GPIIb-IIIa receptor inhibitors: What the interventional radiologist needs to know

Lawrence V. Hofmann, Mahmood Razavi, Aravind Arepally, Joel P. Reginelli, Jon R Resar, Jean Francois Geschwind, Frank Corl

Research output: Contribution to journalArticle

Abstract

The glycoprotein IIb-IIIa (GPIIb-IIIa) receptor inhibitors have established themselves as first line therapy in the treatment of acute coronary syndromes (ACS) and percutaneous coronary intervention (PCI). The benefit of these agents rests in their ability to attenuate the deleterious effects of platelet activation, both at the site of an inflamed vessel wall (due to a ruptured plaque or PCI) and in the microcirculation as a result of embolization. Based on these results, interventional radiologists are beginning to explore the potential of using GPIIb-IIIa inhibitors during interventions in the peripheral circulation. This paper reviews the molecular biology of the GPIIb-IIIa receptor, the pharmacology of the GPIIb-IIIa receptor inhibitors, the current coronary and peripheral vascular literature as it pertains to the GPIIb-IIIa receptor inhibitors, and potential future applications of the GPIIb-IIIa receptor inhibitors in the peripheral circulation.

Original languageEnglish (US)
Pages (from-to)361-367
Number of pages7
JournalCardioVascular and Interventional Radiology
Volume24
Issue number6
DOIs
StatePublished - 2001

Fingerprint

Platelet Glycoprotein GPIIb-IIIa Complex
Percutaneous Coronary Intervention
Platelet Activation
Acute Coronary Syndrome
Microcirculation
Blood Vessels
Radiologists
Molecular Biology
Pharmacology
Therapeutics

Keywords

  • Abciximab, tirofiban, eptifibatide
  • Glycoprotein IIb-IIIa inhibitor
  • Glycoprotein IIb-IIIa receptor
  • Platelet aggregation

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Cite this

GPIIb-IIIa receptor inhibitors : What the interventional radiologist needs to know. / Hofmann, Lawrence V.; Razavi, Mahmood; Arepally, Aravind; Reginelli, Joel P.; Resar, Jon R; Geschwind, Jean Francois; Corl, Frank.

In: CardioVascular and Interventional Radiology, Vol. 24, No. 6, 2001, p. 361-367.

Research output: Contribution to journalArticle

Hofmann, Lawrence V. ; Razavi, Mahmood ; Arepally, Aravind ; Reginelli, Joel P. ; Resar, Jon R ; Geschwind, Jean Francois ; Corl, Frank. / GPIIb-IIIa receptor inhibitors : What the interventional radiologist needs to know. In: CardioVascular and Interventional Radiology. 2001 ; Vol. 24, No. 6. pp. 361-367.
@article{7a169b173e1e4ee0903f58088e9defba,
title = "GPIIb-IIIa receptor inhibitors: What the interventional radiologist needs to know",
abstract = "The glycoprotein IIb-IIIa (GPIIb-IIIa) receptor inhibitors have established themselves as first line therapy in the treatment of acute coronary syndromes (ACS) and percutaneous coronary intervention (PCI). The benefit of these agents rests in their ability to attenuate the deleterious effects of platelet activation, both at the site of an inflamed vessel wall (due to a ruptured plaque or PCI) and in the microcirculation as a result of embolization. Based on these results, interventional radiologists are beginning to explore the potential of using GPIIb-IIIa inhibitors during interventions in the peripheral circulation. This paper reviews the molecular biology of the GPIIb-IIIa receptor, the pharmacology of the GPIIb-IIIa receptor inhibitors, the current coronary and peripheral vascular literature as it pertains to the GPIIb-IIIa receptor inhibitors, and potential future applications of the GPIIb-IIIa receptor inhibitors in the peripheral circulation.",
keywords = "Abciximab, tirofiban, eptifibatide, Glycoprotein IIb-IIIa inhibitor, Glycoprotein IIb-IIIa receptor, Platelet aggregation",
author = "Hofmann, {Lawrence V.} and Mahmood Razavi and Aravind Arepally and Reginelli, {Joel P.} and Resar, {Jon R} and Geschwind, {Jean Francois} and Frank Corl",
year = "2001",
doi = "10.1007/s00270-001-0035-5",
language = "English (US)",
volume = "24",
pages = "361--367",
journal = "CardioVascular and Interventional Radiology",
issn = "7415-5101",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - GPIIb-IIIa receptor inhibitors

T2 - What the interventional radiologist needs to know

AU - Hofmann, Lawrence V.

AU - Razavi, Mahmood

AU - Arepally, Aravind

AU - Reginelli, Joel P.

AU - Resar, Jon R

AU - Geschwind, Jean Francois

AU - Corl, Frank

PY - 2001

Y1 - 2001

N2 - The glycoprotein IIb-IIIa (GPIIb-IIIa) receptor inhibitors have established themselves as first line therapy in the treatment of acute coronary syndromes (ACS) and percutaneous coronary intervention (PCI). The benefit of these agents rests in their ability to attenuate the deleterious effects of platelet activation, both at the site of an inflamed vessel wall (due to a ruptured plaque or PCI) and in the microcirculation as a result of embolization. Based on these results, interventional radiologists are beginning to explore the potential of using GPIIb-IIIa inhibitors during interventions in the peripheral circulation. This paper reviews the molecular biology of the GPIIb-IIIa receptor, the pharmacology of the GPIIb-IIIa receptor inhibitors, the current coronary and peripheral vascular literature as it pertains to the GPIIb-IIIa receptor inhibitors, and potential future applications of the GPIIb-IIIa receptor inhibitors in the peripheral circulation.

AB - The glycoprotein IIb-IIIa (GPIIb-IIIa) receptor inhibitors have established themselves as first line therapy in the treatment of acute coronary syndromes (ACS) and percutaneous coronary intervention (PCI). The benefit of these agents rests in their ability to attenuate the deleterious effects of platelet activation, both at the site of an inflamed vessel wall (due to a ruptured plaque or PCI) and in the microcirculation as a result of embolization. Based on these results, interventional radiologists are beginning to explore the potential of using GPIIb-IIIa inhibitors during interventions in the peripheral circulation. This paper reviews the molecular biology of the GPIIb-IIIa receptor, the pharmacology of the GPIIb-IIIa receptor inhibitors, the current coronary and peripheral vascular literature as it pertains to the GPIIb-IIIa receptor inhibitors, and potential future applications of the GPIIb-IIIa receptor inhibitors in the peripheral circulation.

KW - Abciximab, tirofiban, eptifibatide

KW - Glycoprotein IIb-IIIa inhibitor

KW - Glycoprotein IIb-IIIa receptor

KW - Platelet aggregation

UR - http://www.scopus.com/inward/record.url?scp=0035688882&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035688882&partnerID=8YFLogxK

U2 - 10.1007/s00270-001-0035-5

DO - 10.1007/s00270-001-0035-5

M3 - Article

C2 - 11907740

AN - SCOPUS:0035688882

VL - 24

SP - 361

EP - 367

JO - CardioVascular and Interventional Radiology

JF - CardioVascular and Interventional Radiology

SN - 7415-5101

IS - 6

ER -